Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Mohanad Nada

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

M.H. Nada1, A.J. Hussein2, H. Wang3, C.T. Morita3

Author affiliations

  • 1 Medical Sciences, The American University of Iraq Sulaimani, 46001 - Sulaymaniyah/IQ
  • 2 Ministry of Health/ Salahuddin Diroctorate, Tikrit/IQ
  • 3 Internal Medicine, The University of Iowa, 52240 - Iowa City/US
More

Resources

During cancer development, IL-18 plays both positive and negative roles. IL-18 can promote tumor progression or metastasis, mainly through its effect on VCAM-1 and VEGF production. In contrast, IL-18 has been proven to enhance immunity against several kinds of tumors including melanoma and liver cancer. Due to its impact on IFN-γ production, IL-18 enhances anti-tumor activity by NK and Th1. We have previously shown that pulse stimulation with zoledronate and IL-2 or IL-15 greatly enhance the expansion, and anti-tumor activity of Vγ2Vδ2 T cells. Given the importance of IL-18 on the expansion, differentiation, and function of NK and Th1 cells, we hypothesized that expansion, memory and anti-immunity function of Vγ2Vδ2 T cells can be further optimized by using IL-18 in combination with IL-2 or IL-15 cytokines in prostate cancer settings.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings